Can a Person Take Ezetimibe, a Statin, and Repatha Together?
Yes, a person can absolutely take ezetimibe, a statin, and Repatha (alirocumab) together—this triple combination therapy is explicitly recommended and FDA-approved for patients with high cardiovascular risk who need aggressive LDL-C lowering. 122
Evidence-Based Rationale
The 2026 ACC/AHA guidelines provide the strongest and most recent evidence supporting this combination. For adults with clinical ASCVD at very high risk on maximally tolerated statin therapy, ezetimibe and/or a PCSK9 monoclonal antibody (like Repatha) should be added to achieve LDL-C goals <55 mg/dL and non-HDL-C <85 mg/dL. 1 This is a Class 1 (strongest) recommendation with Level A evidence.
The FDA labeling for ezetimibe explicitly states it is indicated "in combination with a statin, and other LDL-C lowering therapies" for reducing elevated LDL-C levels. 22 This directly encompasses the use of PCSK9 inhibitors like Repatha alongside statins.
Clinical Algorithm for Triple Therapy
When to use all three medications together:
- Start with maximally tolerated statin therapy as the foundation
- Add ezetimibe if LDL-C remains ≥70 mg/dL (1.8 mmol/L) in high-risk patients or ≥55 mg/dL (1.4 mmol/L) in very high-risk patients 13
- Add Repatha (alirocumab) if LDL-C on statin plus ezetimibe remains ≥100 mg/dL (2.6 mmol/L) or if the patient hasn't reached their goal 33
Very high-risk criteria include: history of multiple major ASCVD events (recent ACS, prior MI, ischemic stroke, symptomatic PAD) or one major ASCVD event plus multiple high-risk conditions (age >65, coronary revascularization, current smoking, diabetes, heart failure, hypertension, LDL-C >100 mg/dL despite statin + ezetimibe). 1
Safety Profile
This triple combination is safe and well-tolerated. Multiple international guidelines (Canadian Cardiovascular Society, European Society of Cardiology, NICE) all endorse this sequential add-on approach without safety concerns. 33333
The most common adverse events are:
- Injection site reactions with Repatha (typically mild-moderate)
- Upper respiratory infections, diarrhea, arthralgia with ezetimibe (similar to placebo rates) 2
- No significant increase in serious adverse events with combination therapy 456
Key Clinical Pearls
Dosing flexibility: Repatha can be started at 75 mg every 2 weeks and uptitrated to 150 mg every 2 weeks if LDL-C goals aren't met at 8 weeks. 78 This allows individualized therapy based on response.
Timing consideration: If the patient is also on a bile acid sequestrant, administer ezetimibe ≥2 hours before or ≥4 hours after the sequestrant to avoid reduced absorption. 2
Cost and access: While the combination is medically appropriate, PCSK9 inhibitors like Repatha are expensive. However, the 2026 guidelines explicitly state that selection should be "based on degree of LDL-C lowering needed and patient preference," acknowledging this reality. 1
Evidence Quality
The recommendation for triple therapy is supported by:
- Class 1, Level A evidence from the most recent 2026 ACC/AHA guidelines 1
- Consistent endorsement across multiple international guidelines (ESC/EAS, Canadian, NICE) 33333
- FDA approval explicitly permitting this combination 22
- Clinical trial data demonstrating superior LDL-C reduction with combination therapy versus monotherapy 9510
The evidence overwhelmingly supports that this triple combination is not only safe but represents optimal evidence-based therapy for high-risk patients requiring aggressive lipid lowering to reduce cardiovascular morbidity and mortality.